Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tryp Therapeutics Inc (OP: TRYPF )

N/A UNCHANGED
Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tryp Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
Via ACCESSWIRE
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger details now! 
Via Benzinga
BioMedNewsBreaks — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited
Via Investor Brand Network
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
Via Investor Brand Network
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders
Via Investor Brand Network
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver
Via Investor Brand Network
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Via ACCESSWIRE
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’
Via Investor Brand Network
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Dosing of First Patient in Phase 2a TRP-8802 Clinical Trial
Via Investor Brand Network
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited
Via Investor Brand Network
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement
Via Investor Brand Network
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement
Via Investor Brand Network
Exposures Product Safety
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Life Sciences Exec as New CEO
Via Investor Brand Network
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Reports on the Passing of Director David Tousley
Via Investor Brand Network
With Great Sadness Tryp Announces the Passing of David Tousley, Director
Via ACCESSWIRE
Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy's Garden And More
GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote 
Via Benzinga
Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital... 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.